These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26510727)

  • 41. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age.
    Díez-Domingo J; Sáez-Llorens X; Rodriguez-Weber MA; Epalza C; Chatterjee A; Chiu CH; Lin CY; Berry AA; Martinón-Torres F; Baquero-Artigao F; Langley JM; Ramos Amador JT; Domachowske JB; Huang LM; Chiu NC; Esposito S; Moris P; Lien-Anh Nguyen T; Nikic V; Woo W; Zhou Y; Dieussaert I; Leach A; Gonzalez Lopez A; Vanhoutte N
    J Infect Dis; 2023 May; 227(11):1293-1302. PubMed ID: 36484484
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
    Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
    Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
    Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
    JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
    Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
    Afolabi MO; Ishola D; Manno D; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Greenwood B; Leyssen M; Douoguih M; Leigh B; Watson-Jones D;
    Lancet Infect Dis; 2022 Jan; 22(1):110-122. PubMed ID: 34529962
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
    Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children.
    McFarland EJ; Karron RA; Muresan P; Cunningham CK; Libous J; Perlowski C; Thumar B; Gnanashanmugam D; Moye J; Schappell E; Barr E; Rexroad V; Fearn L; Spector SA; Aziz M; Cielo M; Beneri C; Wiznia A; Luongo C; Collins P; Buchholz UJ
    J Infect Dis; 2020 Feb; 221(4):534-543. PubMed ID: 31758177
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life.
    Hosman T; van Heesbeen R; Bastian AR; Hu W; Comeaux C; Ligtenberg N; van Montfort B; Callendret B; Heijnen E
    Hum Vaccin Immunother; 2024 Dec; 20(1):2344970. PubMed ID: 38783590
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Passive and active immunization against respiratory syncytial virus for the young and old.
    Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intranasal parainfluenza virus type 5 (PIV5)-vectored RSV vaccine is safe and immunogenic in healthy adults in a phase 1 clinical study.
    Spearman P; Jin H; Knopp K; Xiao P; Gingerich MC; Kidd J; Singh K; Tellier M; Radziewicz H; Wu S; McGregor M; Freda B; Wang Z; John SP; Villinger FJ; He B
    Sci Adv; 2023 Oct; 9(43):eadj7611. PubMed ID: 37878713
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A prime-boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus.
    Fu YH; He JS; Wang XB; Zheng XX; Wu Q; Xie C; Zhang M; Wei W; Tang Q; Song JD; Qu JG; Hong T
    Biochem Biophys Res Commun; 2010 Apr; 395(1):87-92. PubMed ID: 20350532
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants.
    Madhi SA; Polack FP; Piedra PA; Munoz FM; Trenholme AA; Simões EAF; Swamy GK; Agrawal S; Ahmed K; August A; Baqui AH; Calvert A; Chen J; Cho I; Cotton MF; Cutland CL; Englund JA; Fix A; Gonik B; Hammitt L; Heath PT; de Jesus JN; Jones CE; Khalil A; Kimberlin DW; Libster R; Llapur CJ; Lucero M; Pérez Marc G; Marshall HS; Masenya MS; Martinón-Torres F; Meece JK; Nolan TM; Osman A; Perrett KP; Plested JS; Richmond PC; Snape MD; Shakib JH; Shinde V; Stoney T; Thomas DN; Tita AT; Varner MW; Vatish M; Vrbicky K; Wen J; Zaman K; Zar HJ; Glenn GM; Fries LF;
    N Engl J Med; 2020 Jul; 383(5):426-439. PubMed ID: 32726529
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Respiratory Syncytial Virus Maternal Vaccination in Infants below 6 Months of Age: Meta-Analysis of Safety, Immunogenicity, and Efficacy.
    Mapindra MP; Mahindra MP; McNamara P; Semple MG; Clark H; Madsen J
    Neonatology; 2024; 121(3):271-282. PubMed ID: 38286126
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.
    Venkatraman N; Anagnostou N; Bliss C; Bowyer G; Wright D; Lövgren-Bengtsson K; Roberts R; Poulton I; Lawrie A; Ewer K; V S Hill A
    Vaccine; 2017 Oct; 35(45):6208-6217. PubMed ID: 28941620
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65.
    Buynak R; Cannon K; DeAtkine D; Kirby J; Usdan L; Bhavsar A; Gérard C; Kuznetsova A; Jayadev A; Amare H; Valenciano S; Meyer N
    Infect Dis Ther; 2024 Aug; 13(8):1789-1805. PubMed ID: 38981954
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
    Tapia MD; Sow SO; Ndiaye BP; Mbaye KD; Thiongane A; Ndour CT; Mboup S; Ake JA; Keshinro B; Akintunde GA; Kinge TN; Vernet G; Bigna JJ; Oguche S; Koram KA; Asante KP; Hogrefe WR; Günther S; Naficy A; De Ryck I; Debois M; Bourguignon P; Jongert E; Ballou WR; Koutsoukos M; Roman F;
    Lancet Infect Dis; 2020 Jun; 20(6):707-718. PubMed ID: 32199491
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants.
    Muňoz FM; Swamy GK; Hickman SP; Agrawal S; Piedra PA; Glenn GM; Patel N; August AM; Cho I; Fries L
    J Infect Dis; 2019 Oct; 220(11):1802-1815. PubMed ID: 31402384
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.
    Wiegand MA; Gori-Savellini G; Gandolfo C; Papa G; Kaufmann C; Felder E; Ginori A; Disanto MG; Spina D; Cusi MG
    J Virol; 2017 May; 91(10):. PubMed ID: 28250126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.